(28 days)
Not Found
No
The device description focuses on standard immunoassay technology and pre-defined cutoff values for interpretation, with no mention of AI or ML algorithms.
No.
This device is an in vitro diagnostic test used to aid in the evaluation of patients with suspected traumatic brain injury to determine the need for a CT scan, it does not provide therapy or treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is an "in vitro diagnostic chemiluminescent microparticle immunoassays" and is used "to aid in the evaluation of patients... to assist in determining the need for a CT (computed tomography) scan of the head." This indicates its role in disease diagnosis or aiding in diagnostic procedures.
No
The device is an in vitro diagnostic (IVD) test that involves physical components (reagents, microparticles) and requires a specific hardware system (ARCHITECT i1000SR System) to perform the quantitative measurements. While it includes software for interpreting results, it is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The document explicitly states "The TBI test is a panel of in vitro diagnostic chemiluminescent microparticle immunoassays (CMIA)..." and describes its use for quantitative measurements of biomarkers in human plasma and serum to aid in the evaluation of patients. This directly aligns with the definition of an in vitro diagnostic device, which is used to examine specimens taken from the human body to provide information for diagnosis, monitoring, or treatment.
- Device Description: The description further clarifies that the test is a "panel of in vitro diagnostic quantitative measurements."
- Intended User/Care Setting: The test is intended for use in "clinical laboratory settings by healthcare professionals," which is a typical environment for IVD use.
The document consistently uses the term "in vitro diagnostic" and describes the device's function as analyzing biological samples outside of the body to provide diagnostic information.
N/A
Intended Use / Indications for Use
The TBI test is a panel of in vitro diagnostic chemiluminescent microparticle immunoassays (CMIA) used for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in human plasma and serum and provides a semi-quantitative interpretation of test results derived from these measurements using the ARCHITECT i1000SR System.
The interpretation of test results is used, in conjunction with other clinical information, to aid in the evaluation of patients, 18 years of age or older, presenting with suspected mild traumatic brain injury (Glasgow Coma Scale score 13-15) within 12 hours of injury, to assist in determining the need for a CT (computed tomography) scan of the head. A negative test result is associated with the absence of acute intracranial lesions visualized on a head CT scan.
The TBI test is intended for use in clinical laboratory settings by healthcare professionals.
Product codes
QAT
Device Description
The TBI test is a panel of in vitro diagnostic quantitative measurements of GFAP and UCH-L1 and provides a semi-quantitative interpretation of GFAP and UCH-L1 in human plasma and serum.
GFAP:
This assay is an automated, two-step immunoassay for the quantitative measurement of GFAP in human plasma and serum using chemiluminescent microparticle immunoassay (CMIA) technology.
Sample, anti-GFAP coated paramagnetic microparticles, and assay specific diluent are combined and incubated. The GFAP present in the sample binds to the anti-GFAP coated microparticles. The mixture is washed. Anti-GFAP acridinium-labeled conjugate is added to create a reaction mixture and incubated. Following a wash cycle, Pre-Trigger and Trigger Solutions are added.
The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of GFAP in the sample and the RLU detected by the system optics.
UCH-L1:
This assay is an automated, two-step immunoassay for the quantitative measurement of UCH-L1 in human plasma and serum using CMIA technology.
Sample, anti-UCH-L1 coated paramagnetic microparticles, and assay specific diluent are combined and incubated. The UCH-L1 present in the sample binds to the anti-UCH-L1 coated microparticles. The mixture is washed. Anti-UCH-L1 acridinium-labeled conjugate is added to create a reaction mixture and incubated.
Following a wash cycle, Pre-Trigger and Trigger Solutions are added.
The resulting chemiluminescent reaction is measured as an RLU. There is a direct relationship between the amount of UCH-L1 in the sample and the RLU detected by the system optics.
Interpretation of Results:
The assay cutoffs were established to be 35.0 pg/mL (35.0 ng/L) for GFAP and 400.0 pg/mL (400.0 ng/L) for UCH-L1.
The GFAP and UCH-L1 results are reported separately and the software provides a TBI interpretation relative to the respective cutoff values as shown in the following table.
| Specification for Constituent Assay Results | TBI Result | TBI Interpretation |
|---|---|---|
| GFAP and UCH-L1 below (" or "" should be considered above the cutoff and a result flagged " |
§ 866.5830 Brain trauma assessment test.
(a)
Identification. A brain trauma assessment test is a device that consists of reagents used to detect and measure brain injury biomarkers in human specimens. The measurements aid in the evaluation of patients with suspected mild traumatic brain injury in conjunction with other clinical information to assist in determining the need for head imaging per current standard of care.(b)
Classification. Class II (special controls). The special controls for this device are:(1) The 21 CFR 809.10(b) compliant labeling must include detailed descriptions of and results from performance testing conducted to evaluate precision, accuracy, linearity, analytical sensitivity, interference, and cross-reactivity. This information must include the following:
(i) Performance testing of device precision must, at minimum, use one unmodified clinical specimen from the intended use population with concentration of the brain injury biomarker(s) near the medical decision point. Contrived specimens that have been generated from pooling of multiple samples or spiking of purified analyte to cover the measuring range may be used, but the contrived samples must be prepared to mimic clinical specimens as closely as possible. This testing must evaluate repeatability and reproducibility using a protocol from an FDA-recognized standard.
(ii) Device performance data must be demonstrated through a clinical study and must include the following:
(A) Data demonstrating clinical validity including the clinical sensitivity and specificity, and positive and negative predictive value of the test in the intended use population of patients with suspected mild traumatic brain injury (
i.e., Glasgow Coma Score (GCS) of 13-15), or equivalent standard of care for determination of severity of traumatic brain injury (TBI).(B) Study must be performed using the operators and in settings that are representative of the types of operators and settings for which the device is intended to be used.
(C) All eligible subjects must meet the well-defined study inclusion and exclusion criteria that define the intended use population. The prevalence of diseased or injured subjects in the study population must reflect the prevalence of the device's intended use population, or alternatively, statistical measures must be used to account for any bias due to enrichment of subpopulations of the intended use population.
(D) All eligible subjects must have undergone a head computerized tomography (CT) scan or other appropriate clinical diagnostic standard used to determine the presence of an intracranial lesion as part of standard of care and must also be evaluated by the subject device. All clinical diagnostic standards used in the clinical study must follow standard clinical practice in the United States.
(E) Relevant demographic variables and baseline characteristics including medical history and neurological history. In addition, head injury characteristics, neurological assessments, and physical evidence of trauma must be provided for each subject. This information includes but is not limited to the following: Time since head injury, time from head injury to CT scan, time from head injury to blood draw, GCS score or equivalent, experience of loss of consciousness, presence of confusion, episodes of vomiting, post-traumatic amnesia characteristics, presence of post-traumatic seizures, drug or alcohol intoxication, mechanism of injury, acute intracranial lesion type, neurosurgical lesion, and cranial fracture.
(F) Each CT scan or other imaging result must be independently evaluated in a blinded manner by at least two board-certified radiologists to determine whether it is positive or negative as defined by the presence or absence of acute intracranial lesions. This independent review must be conducted without access to test results of the device. Prior to conducting the review, the criteria and procedures to be followed for scoring the images must be established, including the mechanism for determining consensus.
(G) All the clinical samples must be tested with the subject device blinded to the TBI status and the neurological-lesion-status of the subject.
(H) Details on how missing values in data are handled must be provided.
(I) For banked clinical samples, details on storage conditions and storage period must be provided. In addition, a specimen stability study must be conducted for the duration of storage to demonstrate integrity of archived clinical samples. The samples evaluated in the assay test development must not be used to establish the clinical validity of the assays.
(iii) Performance testing of device analytical specificity must include the most commonly reported concomitant medications present in specimens from the intended use population. Additionally, potential cross-reacting endogenous analytes must be evaluated at the highest concentration reported in specimens from the intended use population.
(iv) Expected/reference values generated by testing a statistically appropriate number of samples from apparently healthy normal individuals.
(2) The 21 CFR 809.10(a) and (b) compliant labeling must include the following limitations:
(i) A limiting statement that this device is not intended to be used a stand-alone device but as an adjunct to other clinical information to aid in the evaluation of patients who are being considered for standard of care neuroimaging.
(ii) A limiting statement that reads “A negative result is generally associated with the absence of acute intracranial lesions. An appropriate neuroimaging method is required for diagnosis of acute intracranial lesions.”
(iii) As applicable, a limiting statement that reads “This device is for use by laboratory professionals in a clinical laboratory setting.”
0
Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 29, 2023
Abbott Laboratories Lisa Kelly Associate Director Regulatory Affairs 100 Abbott Park Road Dept.09AA, Building CP1 Abbott Park, Illinois 60064
Re: K232669
Trade/Device Name: TBI Regulation Number: 21 CFR 866.5830 Regulation Name: Brain trauma assessment test Regulatory Class: Class II Product Code: QAT Dated: August 31, 2023 Received: September 1, 2023
Dear Lisa Kelly:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part
Page 2
820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Ying Mao -S
Ying Mao, Ph.D. Branch Chief Division of Immunology and Hematology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health
2
Indications for Use
| Submission Number (if known) | K232669 |
|---|---|
| Device Name |
TBI
Indications for Use (Describe)
The TBI test is a panel of in vitro diagnostic chemiluminescent microparticle immunoassays (CMIA) used for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in human plasma and serum and provides a semi-quantitative interpretation of test results derived from these measurements using the ARCHITECT i1000SR System.
The interpretation of test results is used, in conjunction with other clinical information, to aid in the evaluation of patients, 18 years of age or older, presenting with suspected mild traumatic brain injury (Glasgow Coma Scale score 13-15) within 12 hours of injury, to assist in determining the need for a CT (computed tomography) scan of the head. A negative test result is associated with the absence of acute intracranial lesions visualized on a head CT scan.
The TBI test is intended for use in clinical laboratory settings by healthcare professionals.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D)
er-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR § 807.92.
I. Applicant Name
Date summary prepared: September 29, 2023
Abbott Diagnostics Department 09AA, Building CP01 100 Abbott Park Road Abbott Park, IL 60064
Primary contact person for all communications:
Lisa Kelly, Associate Director of Regulatory Affairs Abbott Laboratories lisa.kelly(@abbott.com Phone (224) 668-8849 Fax (224) 280-2358
Secondary contact person for all communications:
Noah Lermer, PhD, Director of Regulatory Affairs Abbott Laboratories noah.lermer@abbott.com Phone (224) 214-7838 Fax (224) 667-1221
II. Device Name
TBI
Reagents
Trade Name: Glial fibrillary acidic protein (GFAP) Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) Device Classification: Class II (Special controls) Classification Name: Brain trauma assessment test Governing Regulation: 21 CFR § 866.5830 Product Code: QAT
4
III. Predicate Device
TBI K223602
IV. Description of Device
The TBI test is a panel of in vitro diagnostic quantitative measurements of GFAP and UCH-L1 and provides a semi-quantitative interpretation of GFAP and UCH-L1 in human plasma and serum.
GFAP:
This assay is an automated, two-step immunoassay for the quantitative measurement of GFAP in human plasma and serum using chemiluminescent microparticle immunoassay (CMIA) technology.
Sample, anti-GFAP coated paramagnetic microparticles, and assay specific diluent are combined and incubated. The GFAP present in the sample binds to the anti-GFAP coated microparticles. The mixture is washed. Anti-GFAP acridinium-labeled conjugate is added to create a reaction mixture and incubated. Following a wash cycle, Pre-Trigger and Trigger Solutions are added.
The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of GFAP in the sample and the RLU detected by the system optics.
UCH-L1:
This assay is an automated, two-step immunoassay for the quantitative measurement of UCH-L1 in human plasma and serum using CMIA technology.
Sample, anti-UCH-L1 coated paramagnetic microparticles, and assay specific diluent are combined and incubated. The UCH-L1 present in the sample binds to the anti-UCH-L1 coated microparticles. The mixture is washed. Anti-UCH-L1 acridinium-labeled conjugate is added to create a reaction mixture and incubated.
5
Following a wash cycle, Pre-Trigger and Trigger Solutions are added.
The resulting chemiluminescent reaction is measured as an RLU. There is a direct relationship between the amount of UCH-L1 in the sample and the RLU detected by the system optics.
Interpretation of Results
The assay cutoffs were established to be 35.0 pg/mL (35.0 ng/L) for GFAP and 400.0 pg/mL (400.0 ng/L) for UCH-L1.
The GFAP and UCH-L1 results are reported separately and the software provides a TBI interpretation relative to the respective cutoff values as shown in the following table.
| Specification for Constituent Assay Results | TBI Result | TBI Interpretation |
|---|---|---|
| GFAP and UCH-L1 below (** The GFAP and UCH-L1 results can be found on the Result Details screen under Constituent Information on the User Interface. |
6
- *** An automated TBI interpretation will not be reported for specimens without a result for GFAP and/or UCH-L1. The GFAP and/or UCH-L1 assay(s) may be retested if needed to obtain a result and a manual TBI interpretation may be required. The TBI interpretation for a specimen is considered positive if the result for either constituent assay (GFAP or UCH-L1) is greater than or equal to the cutoff and no result is obtained for the other assay. The TBI interpretation for a specimen is not reportable if the result for either constituent assay is less than the cutoff and no result is obtained for the other assay.
In the case of a flagged ">" or "" should be considered above the cutoff and a result flagged "in vitro
diagnostic chemiluminescent
microparticle immunoassays (CMIA)
used for the quantitative
measurements of glial fibrillary acidic
protein (GFAP) and ubiquitin
carboxyl-terminal hydrolase L1
(UCH-L1) in human plasma and
serum and provides a semi-
quantitative interpretation of test
results derived from these
measurements using the Alinity i
system.
The interpretation of test results is
used, in conjunction with other
clinical information, to aid in the
evaluation of patients, 18 years of age
or older, presenting with suspected
mild traumatic brain injury (Glasgow
Coma Scale score 13-15) within
12 hours of injury, to assist in
determining the need for a CT
(computed tomography) scan of the
head. A negative test result is
associated with the absence of acute
intracranial lesions visualized on a
head CT scan.
The TBI test is intended for use in
clinical laboratory settings by
healthcare professionals. | The TBI test is a panel of in vitro
diagnostic chemiluminescent
microparticle immunoassays (CMIA)
used for the quantitative
measurements of glial fibrillary acidic
protein (GFAP) and ubiquitin
carboxyl-terminal hydrolase L1
(UCH-L1) in human plasma and
serum and provides a semi-
quantitative interpretation of test
results derived from these
measurements using the
ARCHITECT i1000SR System.
The interpretation of test results is
used, in conjunction with other
clinical information, to aid in the
evaluation of patients, 18 years of age
or older, presenting with suspected
mild traumatic brain injury (Glasgow
Coma Scale score 13-15) within
12 hours of injury, to assist in
determining the need for a CT
(computed tomography) scan of the
head. A negative test result is
associated with the absence of acute
intracranial lesions visualized on a
head CT scan.
The TBI test is intended for use in
clinical laboratory settings by
healthcare professionals. |
| Intended Use
Setting | Clinical Laboratory | Same |
| Measurands | GFAP and UCH-L1 | Same |
| Specimen Type | Plasma and serum | Same |
| Assay
Technology | CMIA | Same |
| Characteristics | Cleared Predicate Device:
TBI for Alinity i
(K223602) | Subject Device:
TBI for ARCHITECT |
| Reportable
Result | Quantitative results for GFAP and
UCH-L1 and semi-quantitative
interpretation for TBI | Same |
| Calibrators | GFAP: 6 levels
UCH-L1: 6 levels | Same |
| Controls | GFAP: 3 levels (25.0, 500.0, and
30000.0 pg/mL)
UCH-L1: 3 levels (250.0, 2000.0, and
15000.0 pg/mL) | Same |
| Assay Format | Two separate test kits – one for GFAP
and one for UCH-L1 | Same |
| Sample Volume | GFAP kit: 200 μL
UCH-L1 kit: 150 µL | Same |
| Reportable
Interval
(pg/mL, ng/L) | Analytical Measuring Interval:
GFAP: 6.1 – 42,000.0
UCH-L1: 26.3 – 25,000.0
Reportable Interval:
GFAP: 3.2 - 42,000.0
UCH-L1: 18.3 - 25,000.0 | Same |
| GFAP Cutoff | 35.0 pg/mL (35.0 ng/L) | Same |
| UCH-L1 Cutoff | 400.0 pg/mL (400.0 ng/L) | Same |
| Reagent
formulation | GFAP Reagent Kit
• Microparticles: Anti-GFAP (rabbit, monoclonal) coated microparticles in TRIS buffer with protein (bovine) stabilizer. Minimum concentration: 0.05 % solids. Preservative: ProClin 300.
• Conjugate: Anti-GFAP (mouse, monoclonal) acridinium-labeled conjugate in MES buffer with protein (bovine) stabilizer. Minimum concentration: 0.2 mg/L. Preservative: ProClin 300.
• Assay Specific Diluent: TRIS buffer with protein (bovine) stabilizer. Preservative: ProClin 300. | Same |
| Characteristics | Cleared Predicate Device:
TBI for Alinity i
(K223602) | Subject Device:
TBI for ARCHITECT |
| Reagent
formulation
(continued) | UCH-L1 Reagent Kit
• Microparticles: Anti-UCH-L1
(mouse, monoclonal) coated
microparticles in TRIS buffer with
protein (bovine) stabilizer. Minimum
concentration: 0.05% solids.
Preservative: sodium azide.
• Conjugate: Anti-UCH-L1 (mouse,
monoclonal) acridinium-labeled
conjugate in MES buffer with protein
(bovine) stabilizer. Minimum
concentration: 0.2 mg/L.
Preservative: ProClin 300.
• Assay Specific Diluent: TRIS buffer
with protein (bovine) stabilizer.
Preservative: sodium azide. | Same |
| General Device Characteristic Differences | | |
| Instrument
Platform | Alinity i system | ARCHITECT i1000SR System |
| Reagent
Packaging
Configuration | GFAP Reagent Kit
2 Cartridges x 100 Tests
• 1 cartridge (7.1 mL) Microparticles
• 1 cartridge (6.4 mL) Conjugate
• 1 cartridge (6.4 mL) Assay Specific
Diluent
UCH-L1 Reagent Kit
2 Cartridges x 100 Tests
• 1 cartridge (7.1 mL) Microparticles
• 1 cartridge (12.5 mL) Conjugate
• 1 cartridge (10.5 mL) Assay Specific
Diluent | GFAP Reagent Kit
100 Tests
• 1 bottle (7.4 mL) Microparticles
• 1 bottle (6.7 mL) Conjugate
• 1 bottle (6.7 mL) Assay Specific
Diluent
UCH-L1 Reagent Kit
100 Tests
• 1 bottle (7.4 mL) Microparticles
• 1 bottle (12.0 mL) Conjugate
• 1 bottle (10.9 mL) Assay Specific
Diluent |
8
9
10
VII. Performance Summary:
The TBI test using the GFAP assay and UCH-L1 assay, evaluated on the ARCHITECT i1000SR System, met the pre-defined product requirements for all characteristics evaluated in the verification studies.
| Verification
| Activity | TBI on ARCHITECT i1000SR |
|---|---|
| GFAP 20-Day | |
| Precision | 2.2 to 6.2 %CV for samples with GFAP concentrations from |
| 20.4 to 37,098.8 pg/mL | |
| UCH-L1 20-Day | |
| Precision | 2.2 to 4.5 %CV for samples with UCH-L1 concentrations |
| from 187.6 to 19,645.0 pg/mL | |
| GFAP | |
| Reproducibility | 2.7 to 6.0 %CV for samples with GFAP concentrations from |
| 23.6 to 34,087.5 pg/mL | |
| 1.30 pg/mL SD for sample with GFAP concentration 19.1 pg/mL | |
| UCH-L1 | |
| Reproducibility | 2.4 to 3.9 %CV for samples with UCH-L1 concentrations |
| from 193.0 to 20,363.2 | |
| GFAP | |
| LoB, LoD, LoQ | LoB – 2.0 pg/mL |
| LoD – 3.2 pg/mL | |
| LoQ – 6.1 pg/mL | |
| UCH-L1 | |
| LoB, LoD, LoQ | LoB - 9.2 pg/mL |
| LoD – 18.3 pg/mL | |
| LoQ – 26.3 pg/mL | |
| GFAP Linearity | GFAP 6.1 to 42,000.0 pg/mL |
| UCH-L1 Linearity | UCH-L1 26.3 to 25,000.0 pg/mL |
| Sample Onboard | 2 hours |
| Reagent Onboard/ | |
| Calibration Curve | |
| Storage | 30 days |
11
Comparison Summary
Studies were performed based on guidance from CLSI EP09c, 3rd ed. using the Passing-Bablok regression method.
| | | ARCHITECT
i1000SR
(pg/mL) | | Alinity i
(pg/mL) | | Correlation
Coefficient (r) | | Intercept | | Slope | |
|------------|-----|---------------------------------|---------|----------------------|---------|--------------------------------|-------------|-----------|--------------|----------|-------------|
| Assay | N | Min | Max | Min | Max | R | 95% CI | Estimate | 95% CI | Estimate | 95% CI |
| GFAP | 123 | 7.9 | 32359.2 | 6.5 | 32548.6 | 1.00 | (1.00,1.00) | -0.6 | (-1.1, -0.3) | 1.03 | (1.02,1.05) |
| UCH-
L1 | 123 | 48.7 | 23763.7 | 51.5 | 24127.7 | 1.00 | (1.00,1.00) | -6.0 | (-7.9, -4.0) | 1.06 | (1.05,1.07) |
VIII. Conclusion
The results presented in this Special 510(k) demonstrate that the performance of the subject device (TBI on the ARCHITECT i1000SR) is substantially equivalent to the performance of the predicate device (TBI on the Alinity i system, K2223602).